URGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than only 4.45% of US-listed equities with positive expected earnings growth.
With a price/sales ratio of 1,358.73, UroGen Pharma Ltd has a higher such ratio than 99.52% of stocks in our set.
As for revenue growth, note that URGN's revenue has grown 1,966.67% over the past 12 months; that beats the revenue growth of 99.46% of US companies in our set.
Stocks that are quantitatively similar to URGN, based on their financial statements, market capitalization, and price volatility, are NYMX, OCX, PTN, PRTA, and CRMD.
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
UroGen (URGN) -3.8% in premarket, says Phase 2 trial of RTGel hydrogel formulation in combination with Botox did not meet the primary endpoint of improvement of overactive bladder ((OAB)) symptoms, as measured by the reduction in urinary incontinence episodes per day. The data suggests result may have been because of Botox not effectively...
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units ("RSUs") on June 3, 2020 to eight new employees in connection with their employment with UroGen. These new team members will support the Company’s commercial launch of JelmytoTM (mitomycin) for pyelocalyceal solution, its first approved product.